GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Moreover, the stigma surrounding obesity disproportionately affects lower-income individuals, who are often blamed for their ...

Weight loss drugs, which took the US market by storm, are looking to be a big opportunity for drug makers in India. Several ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Telehealth company Him & Hers Health is taking a very different approach to its Super Bowl ad this year - as its new ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...